IBDEI1SE ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,29916,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29916,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,29916,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,29916,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,29917,0)
 ;;=C92.40^^135^1372^20
 ;;^UTILITY(U,$J,358.3,29917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29917,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,29917,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,29917,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,29918,0)
 ;;=D56.0^^135^1372^21
 ;;^UTILITY(U,$J,358.3,29918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29918,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,29918,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,29918,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,29919,0)
 ;;=D63.1^^135^1372^23
 ;;^UTILITY(U,$J,358.3,29919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29919,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,29919,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,29919,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,29920,0)
 ;;=D63.0^^135^1372^24
 ;;^UTILITY(U,$J,358.3,29920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29920,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,29920,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,29920,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,29921,0)
 ;;=D63.8^^135^1372^22
 ;;^UTILITY(U,$J,358.3,29921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29921,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,29921,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,29921,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,29922,0)
 ;;=C22.3^^135^1372^25
 ;;^UTILITY(U,$J,358.3,29922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29922,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,29922,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,29922,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,29923,0)
 ;;=D61.9^^135^1372^26
 ;;^UTILITY(U,$J,358.3,29923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29923,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,29923,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,29923,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,29924,0)
 ;;=D56.1^^135^1372^28
 ;;^UTILITY(U,$J,358.3,29924,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29924,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,29924,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,29924,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,29925,0)
 ;;=C83.79^^135^1372^29
 ;;^UTILITY(U,$J,358.3,29925,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29925,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,29925,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,29925,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,29926,0)
 ;;=C83.70^^135^1372^30
 ;;^UTILITY(U,$J,358.3,29926,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29926,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,29926,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,29926,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,29927,0)
 ;;=D09.0^^135^1372^37
 ;;^UTILITY(U,$J,358.3,29927,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29927,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,29927,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,29927,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,29928,0)
 ;;=D06.9^^135^1372^38
 ;;^UTILITY(U,$J,358.3,29928,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29928,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,29928,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,29928,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,29929,0)
 ;;=D06.0^^135^1372^40
 ;;^UTILITY(U,$J,358.3,29929,1,0)
 ;;=^358.31IA^4^2
